TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27225876

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 15° angle reverse Trendelenburg position
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 20° angle reverse Trendelenburg position
Number of subjects: 71
Study: 25200399

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: AREDS formulation (AF)
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 989

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study: 23408046

Group type: EXPERIMENTAL
Intervention: Continuous hydrostatic pressure system (group P)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Saline-filled syringe (group C)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 20048183

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA3; 12 mg/m(2)/d x 3 days)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA4; 12 mg/m(2)/d x 4 days)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR; 80 mg/m(2)/d x 3 days)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2; 5 x 10(6) U/m(2) x 5 days each month for 12 months)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Standard doses of idarubicin (IDA3; 12 mg/m(2)/d x 3 days)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Maintenance therapy with rIL-2
Number of subjects: 468
Study: 18221472

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri supplementation
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 16635225

Group type: EXPERIMENTAL
Intervention: rhIL-11 (1 mg once weekly)
Number of subjects: 51

Group type: COMPARATOR
Intervention: prednisolone (60 mg/day)
Number of subjects: 51
Study: 12792544

Group type: EXPERIMENTAL
Intervention: AlloDerm (LifeCell) repair
Number of subjects: 25

Group type: COMPARATOR
Intervention: GoreTex (W.L. Gore) repair
Number of subjects: 25

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 25
Study: 10360200

Group type: EXPERIMENTAL
Intervention: Dyract restorations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tytin restorations
Number of subjects: 0
Study: 7492424

Group type: EXPERIMENTAL
Intervention: Health check with screening for cardiovascular risk factors, lung and liver function, fitness, sight and hearing, and optional HIV test; written feedback from general practitioner
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Health check with screening, written feedback, and opportunity to discuss preventive health with general practitioner
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Discussion with general practitioner
Number of subjects: 1370
Study: 2024739

Group type: EXPERIMENTAL
Intervention: Secobarbital (100 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secobarbital (200 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol (1 g/kg daily)
Number of subjects: 0
Study: 6120716

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol or metoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous frusemide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior oral metoprolol or propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upright tilting
Number of subjects: 0
Study: 30636832

Group type: EXPERIMENTAL
Intervention: Oxytocin 10 units over 2-4 hours (Group A)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Oxytocin 30 units over 8-12 hours (Group B)
Number of subjects: 271
Study: 25911620

Group type: EXPERIMENTAL
Intervention: Prediction model group
Number of subjects: 1164
Study: 24702815

Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.4 U/kg therapeutic dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.8 U/kg high dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 10
Study: 22439919

Group type: EXPERIMENTAL
Intervention: TRAMPOLINE group programme (nine-session manualised intervention)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group programme (same duration, not addiction-specific)
Number of subjects: 218
Study: 20356553

Group type: EXPERIMENTAL
Intervention: RPLS patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal MRI findings)
Number of subjects: 20
Study: 18626423

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg (0.1 cc) of triamcinolone acetonide at the end of surgery
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 72
Study: 16041723

Group type: EXPERIMENTAL
Intervention: Cymbopogon nardus (citronella) undiluted oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pogostemon cablin (patchuli) undiluted oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syzygium aromaticum (clove) undiluted oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zanthoxylum limonella (makaen) undiluted oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clove oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% and 50% concentrations of tested oils
Number of subjects: 0
Study: 12403927

Group type: EXPERIMENTAL
Intervention: Butterbur extract (petasins)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Established antihistamine treatment
Number of subjects: 0
Study: 9972747

Group type: EXPERIMENTAL
Intervention: TEG-guided transfusion algorithm
Number of subjects: 105

Group type: COMPARATOR
Intervention: Routine transfusion therapy
Number of subjects: 105
Study: 8788983

Group type: EXPERIMENTAL
Intervention: Baclofen (GABA receptor ligand) for 3 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sybazon preparation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 2260157

Group type: EXPERIMENTAL
Intervention: Nimodipine (2 mg/hr constant intravenous infusion for 5 days, 120 mg/day orally for another 16 days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7430528

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Digoxin + Pindolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 8
Study: 6355877

Group type: EXPERIMENTAL
Intervention: Extensive plasma exchanges (PE) plus conventional corticosteroid/azathioprine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional corticosteroid/azathioprine treatment
Number of subjects: 0
Study: 31376748

Group type: EXPERIMENTAL
Intervention: Visual feedback weight shift training (WST) with active horizontal headshake (HS)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Visual feedback weight shift training (WST) without HS (NoHS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 33
Study: 29063309

Group type: EXPERIMENTAL
Intervention: Exercise intervention (delivered face-to-face or by telephone)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 337
Study: 27743448

Group type: EXPERIMENTAL
Intervention: Long-term weekly supragingival irrigations with aerosolized 0.5% hydrogen peroxide
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Supragingival irrigation with aerosolized 0.5% hydrogen peroxide
Number of subjects: 43
Study: 25373733

Group type: EXPERIMENTAL
Intervention: Bortezomib plus Bevacizumab (15 mg/kg Bevacizumab and 1.3 mg/m2 Bortezomib)
Number of subjects: 91
Study: 22674882

Group type: EXPERIMENTAL
Intervention: Chromium dinicocysteinate (CDNC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 100
Study: 21677123

Group type: EXPERIMENTAL
Intervention: ALA diet (17% energy from PUFA, 6.5% ALA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LA diet (16.4% energy from PUFA, 3.6% ALA)
Number of subjects: 20
Study: 17510454

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 15704045

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 272

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 272
Study: 12036186

Group type: EXPERIMENTAL
Intervention: 60 degrees passive head up tilt (HUT) in patients with vitamin B12 deficiency
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 60 degrees passive head up tilt (HUT) in patients with diabetes mellitus
Number of subjects: 51

Group type: COMPARATOR
Intervention: 60 degrees passive head up tilt (HUT) in healthy age‐matched control subjects
Number of subjects: 51
Study: 10086212

Group type: EXPERIMENTAL
Intervention: Participatory ergonomics team intervention
Number of subjects: 110
Study: 7484032

Group type: EXPERIMENTAL
Intervention: 20 ml of 1% mepivacaine (10 mg/ml)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 ml of 1% mepivacaine (10 mg/ml)
Number of subjects: 80
Study: 2245751

Group type: EXPERIMENTAL
Intervention: Soft baby carriers (more physical contact)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Infant seats (less contact)
Number of subjects: 49
Study: 7372262

Group type: EXPERIMENTAL
Intervention: Solugastril Gel (3 sachets daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Solugastril Gel combined with Solu-Vetan
Number of subjects: 20
Study: 31891694

Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Surgery (LVRS)
Number of subjects: 0
Study: 30315625

Group type: EXPERIMENTAL
Intervention: Nifedipine combined with sildenafil citrate (SC)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Nifedipine alone
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Nifedipine combined with SC
Number of subjects: 239
Study: 28800989

Group type: EXPERIMENTAL
Intervention: Intraluminal placement of 9-French Arndt bronchial blocker
Number of subjects: 41

Group type: COMPARATOR
Intervention: Extraluminal placement of 9-French Arndt bronchial blocker
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups (Intraluminal and Extraluminal)
Number of subjects: 41
Study: 26308766

Group type: EXPERIMENTAL
Intervention: PEG ASNase
Number of subjects: 990

Group type: COMPARATOR
Intervention: Erwinia ASNase
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Positive antibody titers postinduction
Number of subjects: 990

Group type: COMPARATOR
Intervention: Negative antibody titers
Number of subjects: 990

Group type: COMPARATOR
Intervention: Positive antibody titers
Number of subjects: 990

Group type: COMPARATOR
Intervention: No ASNase postconsolidation
Number of subjects: 990
Study: 23470315

Group type: EXPERIMENTAL
Intervention: Exercise (60 min treadmill run at approximately 70% of maximal oxygen uptake)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (resting)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 20
Study: 20932656

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV) alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV) plus radiotherapy (RT)
Number of subjects: 20
Study: 18489224

Group type: EXPERIMENTAL
Intervention: Laboratory‐induced cold pressor pain
Number of subjects: 132

Group type: COMPARATOR
Intervention: No pain condition
Number of subjects: 132
Study: 16622270

Group type: EXPERIMENTAL
Intervention: Neoadjuvant (primary systemic) treatment for operable breast cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendations from an international expert panel
Number of subjects: 0
Study: 12930572

Group type: EXPERIMENTAL
Intervention: recombinant human FSH (rhFSH) 75 IU FSH/ampoule, 150 IU total for the first 14 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: human menopausal gonadotrophin (HMG) 75 IU FSH and 75 IU LH/ampoule, 150 IU total for the first 14 days
Number of subjects: 50
Study: 11001761

Group type: EXPERIMENTAL
Intervention: Mental stress in lean women
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mental stress in obese women
Number of subjects: 19

Group type: COMPARATOR
Intervention: Mental stress under propranolol in lean women
Number of subjects: 19
Study: 9055522

Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (no history of TBI)
Number of subjects: 74
Study: 8256886

Group type: EXPERIMENTAL
Intervention: Thiorphan (2.5 mg/ml concentration, 0.5 ml nebulized dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3552380

Group type: EXPERIMENTAL
Intervention: Ureteric compression
Number of subjects: 0

Group type: COMPARATOR
Intervention: No ureteric compression
Number of subjects: 0
Study: 29514306

Group type: EXPERIMENTAL
Intervention: Monovalent rotavirus vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural immunity from prior RVD episodes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated cohorts with varying rotavirus incidence rates
Number of subjects: 0
Study: 28647461

Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (tIOL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Peripheral corneal relaxing incisions (PCRI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: PCRI
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tIOL
Number of subjects: 80
Study: 26329347

Group type: EXPERIMENTAL
Intervention: Telmisartan/rosuvastatin fixed-dose combination (80/20 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Coadministration of telmisartan 80 mg and rosuvastatin 20 mg
Number of subjects: 60
Study: 23897106

Group type: EXPERIMENTAL
Intervention: ALBBCG (Bromocresol Green method)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ALBmBCP (Modified Bromocresol Purple method)
Number of subjects: 44
Study: 20079396

Group type: EXPERIMENTAL
Intervention: Group I (microradiography)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Group II (microCT)
Number of subjects: 14
Study: 20467623

Group type: EXPERIMENTAL
Intervention: Immediate loading of dental implants
Number of subjects: 60

Group type: COMPARATOR
Intervention: Early loading of dental implants (6 weeks)
Number of subjects: 60
Study: 16645293

Group type: EXPERIMENTAL
Intervention: Nijmegen Falls Prevention Program (exercise group)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 12580841

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 20 mL injected into the uterus, fallopian tubes, and pelvis
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo normal saline 20 mL injected into the uterus, fallopian tubes, and pelvis
Number of subjects: 78
Study: 11113041

Group type: EXPERIMENTAL
Intervention: abciximab with low-dose weight-adjusted heparin
Number of subjects: 2792

Group type: EXPERIMENTAL
Intervention: abciximab with standard-dose weight-adjusted heparin
Number of subjects: 2792

Group type: COMPARATOR
Intervention: placebo with standard-dose weight-adjusted heparin
Number of subjects: 2792
Study: 8985725

Group type: EXPERIMENTAL
Intervention: Patients with left heart valvular disease (Aortic regurgitation, Mitral regurgitation, Mixed aortic and mitral regurgitation)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Patients with left heart valvular disease
Number of subjects: 55
Study: 1418046

Group type: EXPERIMENTAL
Intervention: 1% flutrimazole skin cream
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2% flutrimazole skin cream
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Excipient only
Number of subjects: 21

Group type: COMPARATOR
Intervention: 1% clotrimazole commercial skin cream
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Systemic tolerance testing
Number of subjects: 21
Study: 3856293

Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1.0 mg PGE2
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 2.0 mg PGE2
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4
Study: 31138456

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (N=151)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Healthy education control (N=156)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 307
Study: 30082027

Group type: EXPERIMENTAL
Intervention: Peer feedback
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Expert feedback
Number of subjects: 100

Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 100
Study: 27348915

Group type: EXPERIMENTAL
Intervention: Needle-pricking therapy at Guanyuan (CV 4) and bilateral sacral plexus nerve, lumbar 1 nerve and greater occipital nerve stimulating points, once a week for 9 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Midodrine tablets prescribed orally, three times a day for 9 weeks
Number of subjects: 36
Study: 24721240

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine Liuweiwuling tablets in combination with entecavir
Number of subjects: 430

Group type: COMPARATOR
Intervention: Entecavir alone (control group)
Number of subjects: 430
Study: 22493375

Group type: EXPERIMENTAL
Intervention: DEBIRI
Number of subjects: 74

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 74
Study: 20472604

Group type: EXPERIMENTAL
Intervention: Positive then negative information
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Negative then positive information
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 18191102

Group type: EXPERIMENTAL
Intervention: Statistical significance tests used in RCTs
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Discussion of clinical significance
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Consideration of statistical power
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Interpretation of effect size
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Interpretation of confidence intervals
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Importance of knowing magnitude and clinical importance of effect
Number of subjects: 193
Study: 15894667

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Past smokers
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Smoking > or =2 packs/d
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Smoking for > or =11 years
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Greater smoking intensity
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Greater smoking duration
Number of subjects: 506
Study: 12519332

Group type: EXPERIMENTAL
Intervention: New collagen barrier (Ossix)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard e-PTFE membrane (Gore-Tex)
Number of subjects: 28
Study: 10364995

Group type: EXPERIMENTAL
Intervention: Nitric oxide 20 ppm
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitrogen (control)
Number of subjects: 60
Study: 7990859

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Granisetron + Dexamethasone
Number of subjects: 408
Study: 1283552

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurse-administered intermittent intramuscular (IM) injections of morphine
Number of subjects: 0
Study: 3004550

Group type: EXPERIMENTAL
Intervention: Antituberculous chemotherapy (2-week course)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Antituberculous chemotherapy including rifampicin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Antituberculous chemotherapy without rifampicin
Number of subjects: 41
Study: 31295009

Group type: EXPERIMENTAL
Intervention: Xinmailong injection (100 mg/2 mL, intravenous drip infusion)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (equal amounts of XI placebo)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Standard treatment plus XI
Number of subjects: 100
Study: 29668900

Group type: EXPERIMENTAL
Intervention: HCoV ARI incidence in infants
Number of subjects: 3505

Group type: EXPERIMENTAL
Intervention: HCoV incidence rate
Number of subjects: 3505

Group type: EXPERIMENTAL
Intervention: HCoV incidence in nonneonates vs neonates
Number of subjects: 3505

Group type: EXPERIMENTAL
Intervention: HCoV ARI incidence related to household factors
Number of subjects: 3505

Group type: EXPERIMENTAL
Intervention: Coinfections with other respiratory viruses
Number of subjects: 3505

Group type: EXPERIMENTAL
Intervention: Seasonal variation of HCoV
Number of subjects: 3505
Study: 26346590

Group type: EXPERIMENTAL
Intervention: Low-intensity maintenance programme (2-hour sessions at 3, 6, and 9 months)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 148
Study: 24269033

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei (HF.A00232) plus levocetirizine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Levocetirizine plus placebo
Number of subjects: 60
Study: 22702508

Group type: EXPERIMENTAL
Intervention: SCH527123, 30 mg daily PO
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 20465448

Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's block with ropivacaine 0.2%
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no sub‐Tenon's block)
Number of subjects: 79
Study: 18753472

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt‐PA)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 15735456

Group type: EXPERIMENTAL
Intervention: Oral fluid test with standard counseling
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Rapid test with standard counseling
Number of subjects: 761

Group type: COMPARATOR
Intervention: Traditional test with standard counseling
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Traditional test with choice of written pretest materials or standard counseling
Number of subjects: 761
Study: 12088977

Group type: COMPARATOR
Intervention: Air group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: N67 group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: N40 group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: N40-c group
Number of subjects: 24
Study: 9546566

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl or bupivacaine
Number of subjects: 100